MARKETS

LiveTV

Gold Rate

Abbott India Ltd.

BSE: 500488 | NSE: ABBOTINDIA |

Represents Equity.Intra - day transactions are permissible and normal trading is done in this category

Series: EQ | ISIN: INE358A01014 | SECTOR: Pharmaceuticals & DrugsPharmaceuticals & Drugs

Success

Alert

Please select a Day.

Info

Open trading A/c Open trading A/c

Abbott India L Abbott India Ltd. | BSE 29912.30 105.45 (0.35%) | NSE 29930.00 125.00 (0.42%) | Trade | Add

BSE Live

Oct 20, 16:01

29912.30 105.45 (0.35%)

Volume

AVERAGE VOLUME

5-Day

1,264

10-Day

823

30-Day

653

578

Prev. Close

29806.85
Open Price

29650.05

Bid Price (Qty.)
29912.30 (1)
Offer Price (Qty.)
29994.90 (1)

NSE Live

Oct 20, 15:42

29930.00 125.00 (0.42%)

Volume

AVERAGE VOLUME

5-Day

5,821

10-Day

5,930

30-Day

8,923

4,662

Prev. Close

29805.00
Open Price

29970.00

Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)

Financials

Print/Copy to Excel : Go

Data Not Available for Cash Flow

Results of Abbott India

12.04.2021

Abbott India Q4 PAT seen up 55.7% YoY to Rs. 172.8 cr: Sharekhan
12.04.2018

Pharma Q4 earnings preview: Tough quarter; US pricing pressure, domestic sales recovery hold key
18.01.2018

Pharma Q3 earnings preview - cos brace for challenging quarter, US and India sales hold key
19.10.2016

Abbott India Q2 PAT seen up 4.7% to Rs 77.5 cr: Centrum

01.01.1970

Results of Pharmaceuticals Sector

22.07.2021

Gland Pharma’s new product play for FY22 holds a lot of promise
15.11.2017

Hold Indoco Remedies; target of Rs 250: ICICI Direct
05.10.2017

Buy Natco Pharma; target of Rs 1065: ICICI Direct
18.07.2017

Cipla Q1 PAT may dip 46.52% YoY to Rs 199.6 cr: KR Choksey

28.02.2017

Sanofi India Q4 net declines 58% to Rs 50.5 cr
27.02.2017

Merck Dec-qtr net up 25% at Rs 18 cr
14.02.2017

Claris Lifesciences net profit up 233 pc at Rs 35 cr in Q3
14.02.2017

Sun Pharma Q3 profit dragged by slowdown in US & India sales

18.07.2017

Cipla Q1 PAT may dip 46.52% YoY to Rs 199.6 cr: KR Choksey
13.02.2017

Sun Pharma Q3 profit seen up 27%; US & India biz may grow 10%
09.02.2017

Aurobindo Q3 profit seen up 14%, revenue may grow 10% on US biz
09.02.2017

Lupin Q3 profit seen up 15% to Rs 609cr, US biz may lift revenue

15.02.2017

Ranbaxy deal to kick in, Halol overhang on Sun Pharma:Brokerages
06.02.2017

Good Q3 but Dr Reddy's still far from sustainable growth: Expert
10.11.2016

Sun Pharma Q2 show healthy but margins unsustainable: Nangra
09.11.2016

Low earnings for Lupin to continue for next 2 qtrs: IIFL

Abbott India Ltd.

Financials

Results of Abbott India

Results of Pharmaceuticals Sector

Quick links

News

Corporate Action

Information

Financials

Annual Report

Peer Comparison

Related Searches